Takeda Ireland Ltd
Takeda Pharmaceutical Company Limited, a global, values-based, R&D-driven biopharmaceutical leader committed to bringing better health and a brighter future to patients by translating science into life-changing medicines, has been established in Ireland since 1997. Across Ireland, Takeda has commercial operations, corporate services and two manufacturing facilities in Bray and Grange Castle (Takeda Ireland Ltd).
Takeda Ireland Ltd - Bray (DP)
Established in 1997 Takeda Ireland – Bray, is a Solid Oral Dosage Facility, which produces, packs and ships key strategic granulates, solid oral dosage tablets and final packaged blockbuster drug products to the worldwide markets including the major US, European, Japanese and valuable emerging markets. Bray produces products for the therapeutic areas of Cardiovascular, Metabolic, Central Nervous System (CNS), Gastro-Intestinal and Oncology.
Bray, currently has over 340 employees and is a shift operation, presently working twenty-four hours a day, seven days a week. To enable this, Takeda Ireland – Bray draws on the expertise of its world-class people, equipment and systems to meet the challenges of competing in our leading-edge markets. Bray has very recently added to its product portfolio by expanding facilities to produce two new oncology drugs - commercial production started at the end of 2020.
Takeda Ireland Ltd - Grange Castle (API, DP and Biologics)
Constructed in 2002, the site now consists of 3 plants and employs over 200 people, with plans to continue expanding into 2021. The site represents a key strategic addition to the group's global production network.
Grange Castle started out developing and producing API's from clinical trial stages through to launch and full commercialisation. In 2017/2018 the site expanded its API operation to include a dedicated plant for the production of API, Drug Product and Packaging to support the production of a high tech oncology product for the treatment of multiple myeloma. In 2019, the Company also established a new standalone modular cell therapy facility dedicated to manufacturing a novel stem cell therapy, locally administered for the potential treatment of certain patients with perianal fistulae associated with Crohn’s disease.